Why the study?
Does moexipril alone or in combination with hydrochlorothiazide effectively lower blood pressure in patients with hypertension?
Does moexipril alone or in combination with hydrochlorothiazide effectively lower blood pressure in patients with hypertension?
Moexipril is a long-acting ACE inhibitor that is effective, well-tolerated, and safe for once-daily treatment of hypertension, either alone or combined with hydrochlorothiazide.
Answers are grounded in this paper and cite their sources.
Supports once-daily moexipril regimens in hypertension; leaves open need for contemporary comparative trials.
Angiotensin-converting enzyme (ACE) inhibitors are effective and safe antihypertensive drugs, with the exception of the rare occasion of angioedema. These drugs have demonstrated additional cardiovascular protective effects to their blood pressure lowering, and their combination with the diuretic hydrochlorothiazide potentiates their antihypertensive effectiveness. Moexipril is a long-acting ACE inhibitor suitable for once-daily administration, and like some ACE inhibitors, moexipril is a prodrug and needs to be hydrolyzed in the liver into its active carboxylic metabolite, moexiprilat, to become effective. Moexipril alone and in combination with low-dose hydrochlorothiazide has been shown in clinical trials to be effective in lowering blood pressure and be well tolerated and safe given in single daily doses. In this review, the pharmacological profile of this drug and its clinical usefulness are discussed.
No takes yet. Share an insight, caveat, or question.
Chrysant et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: